All articles by
FDA expands Wegovy’s indication to reduce cardiovascular risks in overweight or obesity adults
The approval was based on Wegovy’s efficacy and safety results from the SELECT cardiovascular outcomes study in which the drug significantly lowered the MACE risk in comparison to placebo
BeiGene gets FDA accelerated approval for Brukinsa combo to treat R/R FL
The approval was based on the overall response rate (ORR) from the ROSEWOOD study in which ORR was observed at 69% in the Brukinsa plus obinutuzumab arm against 46% in the obinutuzumab group
AstraZeneca to invest £650m in UK to enhance pandemic preparedness
The investment, announced by the UK government as part of Finance Minister Jeremy Hunt’s spring budget, is expected to improve public health protection, pandemic preparedness and AstraZeneca’s UK footprint
Diasorin receives FDA 510(k) clearance for its Liaison Plex® System, the new multiplexing platform of the group, together with the Liaison Plex® Respiratory Panel
Diasorin (FTSE MIB: DIA) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new LIAISON PLEX® platform as well as its first panel of tests, the LIAISON PLEX® Respiratory Flex Assay.
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
Hybribio Calls for Raising International HPV Awareness
March 4th 2024 marks the 7th International HPV Awareness Day, a global campaign proposed by the International Papillomavirus Society (IPVS) since 2018. This year, the theme is One Less Worry. On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
Applied Therapeutics gets FDA priority review for govorestat in classic galactosemia
The FDA has set a PDUFA target action date of 28 August 2024 for the investigational, Aldose Reductase Inhibitor
Greenway and Luma team up on patient engagement solution
Greenway Patient Connect aims to support three daily elements of a patient’s experience – access, communication, and readiness.
GE HealthCare and Biofourmis partner to enhance post-hospital care
Biofourmis’ care-at-home solutions include wearable devices, digital platforms, and in-home services orchestration technology.
Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP
FDA-approved generic provides cost-effective option for treating cancer